1 Study Coverage
1.1 Neuroendocrine Tumor Drug Product Introduction
1.2 Market Segments
1.3 Key Neuroendocrine Tumor Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type
1.4.2 mTOR protein inhibitors
1.4.3 Tyrosine kinase 3 inhibitors
1.4.4 Somatostatin receptor antagonists
1.4.5 Growth hormone releasing factor antagonists
1.4.6 Somatostatin receptor agonists
1.4.7 Others
1.5 Market by Application
1.5.1 Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Neuroendocrine Tumor Drug Market Size, Estimates and Forecasts
2.1.1 Global Neuroendocrine Tumor Drug Revenue 2015-2026
2.1.2 Global Neuroendocrine Tumor Drug Sales 2015-2026
2.2 Global Neuroendocrine Tumor Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Neuroendocrine Tumor Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Neuroendocrine Tumor Drug Competitor Landscape by Players
3.1 Neuroendocrine Tumor Drug Sales by Manufacturers
3.1.1 Neuroendocrine Tumor Drug Sales by Manufacturers (2015-2020)
3.1.2 Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Neuroendocrine Tumor Drug Revenue by Manufacturers
3.2.1 Neuroendocrine Tumor Drug Revenue by Manufacturers (2015-2020)
3.2.2 Neuroendocrine Tumor Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Neuroendocrine Tumor Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Drug Revenue in 2019
3.2.5 Global Neuroendocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Neuroendocrine Tumor Drug Price by Manufacturers
3.4 Neuroendocrine Tumor Drug Manufacturing Base Distribution, Product Types
3.4.1 Neuroendocrine Tumor Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neuroendocrine Tumor Drug Product Type
3.4.3 Date of International Manufacturers Enter into Neuroendocrine Tumor Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Neuroendocrine Tumor Drug Market Size by Type (2015-2020)
4.1.1 Global Neuroendocrine Tumor Drug Sales by Type (2015-2020)
4.1.2 Global Neuroendocrine Tumor Drug Revenue by Type (2015-2020)
4.1.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Neuroendocrine Tumor Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Type (2021-2026)
4.2.3 Neuroendocrine Tumor Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Neuroendocrine Tumor Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Neuroendocrine Tumor Drug Market Size by Application (2015-2020)
5.1.1 Global Neuroendocrine Tumor Drug Sales by Application (2015-2020)
5.1.2 Global Neuroendocrine Tumor Drug Revenue by Application (2015-2020)
5.1.3 Neuroendocrine Tumor Drug Price by Application (2015-2020)
5.2 Neuroendocrine Tumor Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Neuroendocrine Tumor Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Neuroendocrine Tumor Drug Price Forecast by Application (2021-2026)

6 North America
6.1 North America Neuroendocrine Tumor Drug by Country
6.1.1 North America Neuroendocrine Tumor Drug Sales by Country
6.1.2 North America Neuroendocrine Tumor Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Neuroendocrine Tumor Drug Market Facts & Figures by Type
6.3 North America Neuroendocrine Tumor Drug Market Facts & Figures by Application

7 Europe
7.1 Europe Neuroendocrine Tumor Drug by Country
7.1.1 Europe Neuroendocrine Tumor Drug Sales by Country
7.1.2 Europe Neuroendocrine Tumor Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Type
7.3 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Neuroendocrine Tumor Drug by Region
8.1.1 Asia Pacific Neuroendocrine Tumor Drug Sales by Region
8.1.2 Asia Pacific Neuroendocrine Tumor Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Type
8.3 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Application

9 Latin America
9.1 Latin America Neuroendocrine Tumor Drug by Country
9.1.1 Latin America Neuroendocrine Tumor Drug Sales by Country
9.1.2 Latin America Neuroendocrine Tumor Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Neuroendocrine Tumor Drug Market Facts & Figures by Type
9.3 Central & South America Neuroendocrine Tumor Drug Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Neuroendocrine Tumor Drug by Country
10.1.1 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country
10.1.2 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Type
10.3 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Application

11 Company Profiles
11.1 Eisai
11.1.1 Eisai Corporation Information
11.1.2 Eisai Description and Business Overview
11.1.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
11.1.5 Eisai Related Developments
11.2 Exelixis, Inc.
11.2.1 Exelixis, Inc. Corporation Information
11.2.2 Exelixis, Inc. Description and Business Overview
11.2.3 Exelixis, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Exelixis, Inc. Neuroendocrine Tumor Drug Products Offered
11.2.5 Exelixis, Inc. Related Developments
11.3 Foresee Pharmaceuticals, LLC
11.3.1 Foresee Pharmaceuticals, LLC Corporation Information
11.3.2 Foresee Pharmaceuticals, LLC Description and Business Overview
11.3.3 Foresee Pharmaceuticals, LLC Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Products Offered
11.3.5 Foresee Pharmaceuticals, LLC Related Developments
11.4 Hutchison MediPharma Limited
11.4.1 Hutchison MediPharma Limited Corporation Information
11.4.2 Hutchison MediPharma Limited Description and Business Overview
11.4.3 Hutchison MediPharma Limited Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Products Offered
11.4.5 Hutchison MediPharma Limited Related Developments
11.5 Intezyne, Inc
11.5.1 Intezyne, Inc Corporation Information
11.5.2 Intezyne, Inc Description and Business Overview
11.5.3 Intezyne, Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Intezyne, Inc Neuroendocrine Tumor Drug Products Offered
11.5.5 Intezyne, Inc Related Developments
11.6 INVENT Pharmaceuticals, Inc.
11.6.1 INVENT Pharmaceuticals, Inc. Corporation Information
11.6.2 INVENT Pharmaceuticals, Inc. Description and Business Overview
11.6.3 INVENT Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
11.6.5 INVENT Pharmaceuticals, Inc. Related Developments
11.7 Ipsen S.A.
11.7.1 Ipsen S.A. Corporation Information
11.7.2 Ipsen S.A. Description and Business Overview
11.7.3 Ipsen S.A. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Ipsen S.A. Neuroendocrine Tumor Drug Products Offered
11.7.5 Ipsen S.A. Related Developments
11.8 Jiangsu Hengrui Medicine Co., Ltd.
11.8.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
11.8.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
11.8.3 Jiangsu Hengrui Medicine Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Products Offered
11.8.5 Jiangsu Hengrui Medicine Co., Ltd. Related Developments
11.9 Karyopharm Therapeutics, Inc.
11.9.1 Karyopharm Therapeutics, Inc. Corporation Information
11.9.2 Karyopharm Therapeutics, Inc. Description and Business Overview
11.9.3 Karyopharm Therapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Products Offered
11.9.5 Karyopharm Therapeutics, Inc. Related Developments
11.10 Lexicon Pharmaceuticals, Inc.
11.10.1 Lexicon Pharmaceuticals, Inc. Corporation Information
11.10.2 Lexicon Pharmaceuticals, Inc. Description and Business Overview
11.10.3 Lexicon Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Products Offered
11.10.5 Lexicon Pharmaceuticals, Inc. Related Developments
11.1 Eisai
11.1.1 Eisai Corporation Information
11.1.2 Eisai Description and Business Overview
11.1.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Eisai Neuroendocrine Tumor Drug Products Offered
11.1.5 Eisai Related Developments
11.12 Millennium Pharmaceuticals, Inc.
11.12.1 Millennium Pharmaceuticals, Inc. Corporation Information
11.12.2 Millennium Pharmaceuticals, Inc. Description and Business Overview
11.12.3 Millennium Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Millennium Pharmaceuticals, Inc. Products Offered
11.12.5 Millennium Pharmaceuticals, Inc. Related Developments
11.13 MolMed S.p.A.
11.13.1 MolMed S.p.A. Corporation Information
11.13.2 MolMed S.p.A. Description and Business Overview
11.13.3 MolMed S.p.A. Sales, Revenue and Gross Margin (2015-2020)
11.13.4 MolMed S.p.A. Products Offered
11.13.5 MolMed S.p.A. Related Developments
11.14 Northwest Biotherapeutics, Inc.
11.14.1 Northwest Biotherapeutics, Inc. Corporation Information
11.14.2 Northwest Biotherapeutics, Inc. Description and Business Overview
11.14.3 Northwest Biotherapeutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Northwest Biotherapeutics, Inc. Products Offered
11.14.5 Northwest Biotherapeutics, Inc. Related Developments
11.15 Novartis AG
11.15.1 Novartis AG Corporation Information
11.15.2 Novartis AG Description and Business Overview
11.15.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Novartis AG Products Offered
11.15.5 Novartis AG Related Developments
11.16 OctreoPharm Sciences GmbH
11.16.1 OctreoPharm Sciences GmbH Corporation Information
11.16.2 OctreoPharm Sciences GmbH Description and Business Overview
11.16.3 OctreoPharm Sciences GmbH Sales, Revenue and Gross Margin (2015-2020)
11.16.4 OctreoPharm Sciences GmbH Products Offered
11.16.5 OctreoPharm Sciences GmbH Related Developments
11.17 OXiGENE, Inc.
11.17.1 OXiGENE, Inc. Corporation Information
11.17.2 OXiGENE, Inc. Description and Business Overview
11.17.3 OXiGENE, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.17.4 OXiGENE, Inc. Products Offered
11.17.5 OXiGENE, Inc. Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Neuroendocrine Tumor Drug Market Estimates and Projections by Region
12.1.1 Global Neuroendocrine Tumor Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Neuroendocrine Tumor Drug Revenue Forecast by Regions 2021-2026
12.2 North America Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.2.1 North America: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.2.2 North America: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.2.3 North America: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.3.2 Europe: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Neuroendocrine Tumor Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Neuroendocrine Tumor Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Neuroendocrine Tumor Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Neuroendocrine Tumor Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Neuroendocrine Tumor Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Neuroendocrine Tumor Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neuroendocrine Tumor Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer